Murine Pten-/- T-ALL requires non-redundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic exit

Cancer Letters

Volumn 346, Issue 2, 2014, Pages 237-248

  Hagenbeek, Thijs J ^a,b,c   Wu, Xiumin ^c   Choy, Lisa ^c   Sanchez Irizarry, Cheryll ^c   Seshagiri, Somasekar ^c   Stinson, Jeremy ^c   Siebel, Christian W ^c   Spits, Hergen ^a,b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c GENENTECH INC   (United States)

Author keywords

Pten Notch1 T cell leukemia

Indexed keywords

DELTA LIKE 4 PROTEIN; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; DLL4 PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; MTOR PROTEIN, MOUSE; NOTCH1 PROTEIN, MOUSE; PTEN PROTEIN, MOUSE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYMUS; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

MURINAE;

ANIMALS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PTEN PHOSPHOHYDROLASE; RECEPTOR, NOTCH1; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SIGNAL TRANSDUCTION; THYMUS GLAND; TOR SERINE-THREONINE KINASES;

EID: 84896124109     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.12.027     Document Type: Article

References (47)

1. Webb L.M., et al. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J. Immunol. 2005, 175(5):2783-2787.
2. Radtke F., et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999, 10(5):547-558.
3. Hagenbeek T.J., et al. The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling. J. Exp. Med. 2004, 200(7):883-894.
4. Hagenbeek T.J., Spits H. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 2008, 22(3):608-619.
5. Weerkamp F., van Dongen J.J., Staal F.J. Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia. Leukemia 2006, 20(7):1197-1205.
6. Gutierrez A., et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009, 114(3):647-650.
7. Weng A.P., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306(5694):269-271.
8. O'Neil J., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 2007, 204(8):1813-1824.
9. Sanda T., et al. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood 2010, 115(9):1735-1745.
10. Mungamuri S.K., et al. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006, 66(9):4715-4724.
11. Palomero T., et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 2007, 13(10):1203-1210.
12. Medyouf H., et al. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood 2010, 115(6):1175-1184.
13. Kirberg J., Berns A., von Boehmer H. Peripheral T cell survival requires continual ligation of the T cell receptor to major histocompatibility complex-encoded molecules. J. Exp. Med. 1997, 186(8):1269-1275.
14. Heemskerk M.H., et al. Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J. Exp. Med. 1997, 186(9):1597-1602.
15. Jaleco A.C., et al. Genetic modification of human B-cell development: B-cell development is inhibited by the dominant negative helix loop helix factor Id3. Blood 1999, 94(8):2637-2646.
16. Dontje W., et al. Delta-like1-induced Notch1 signaling regulates the human plasmacytoid dendritic cell versus T-cell lineage decision through control of GATA-3 and Spi-B. Blood 2006, 107(6):2446-2452.
17. Kinsella T.M., Nolan G.P. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum. Gene Ther. 1996, 7(12):1405-1413.
18. Ridgway J., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444(7122):1083-1087.
19. Wu Y., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464(7291):1052-1057.
20. Deane J.A., Fruman D.A. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu. Rev. Immunol. 2004, 22:563-598.
21. Kovanen P.E., Leonard W.J. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 2004, 202:67-83.
22. Mao C., et al. Unequal contribution of Akt isoforms in the double-negative to double-positive thymocyte transition. J. Immunol. 2007, 178(9):5443-5453.
23. Barata J.T., et al. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 2001, 98(5):1524-1531.
24. Silva A., et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res. 2011, 71(14):4780-4789.
25. Haks M.C., et al. The CD3gamma chain is essential for development of both the TCRalphabeta and TCRgammadelta lineages. EMBO J. 1998, 17(7):1871-1882.
26. Pear W.S., et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med. 1996, 183(5):2283-2291.
27. Aster J.C., et al. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol. Cell. Biol. 2000, 20(20):7505-7515.
28. O'Neil J., et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006, 107(2):781-785.
29. Besseyrias V., et al. Hierarchy of Notch-Delta interactions promoting T cell lineage commitment and maturation. J. Exp. Med. 2007, 204(2):331-343.
30. Koch U., et al. Delta-like 4 is the essential, nonredundant ligand for Notch1 during thymic T cell lineage commitment. J. Exp. Med. 2008, 205(11):2515-2523.
31. Hozumi K., et al. Delta-like 4 is indispensable in thymic environment specific for T cell development. J. Exp. Med. 2008, 205(11):2507-2513.
32. Ashworth T.D., et al. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood 2010, 116(25):5455-5464.
33. Granville C.A., et al. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin. Cancer Res. 2006, 12(3 Pt 1):679-689.
34. Crazzolara R., et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Brit. J. Haematol. 2001, 115(3):545-553.
35. Till K.J., et al. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 2002, 99(8):2977-2984.
36. Qiuping Z., et al. Selectively increased expression and functions of chemokine receptor CCR9 on CD4+ T cells from patients with T-cell lineage acute lymphocytic leukemia. Cancer Res. 2003, 63(19):6469-6477.
37. Anderson G., Jenkinson E.J. Lymphostromal interactions in thymic development and function. Nat. Rev. Immunol. 2001, 1(1):31-40.
38. Hasserjian R.P., et al. Modulated expression of notch1 during thymocyte development. Blood 1996, 88(3):970-976.
39. Saito T., et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 2003, 18(5):675-685.
40. Dudley D.D., Wang H.C., Sun X.H. Hes1 potentiates T cell lymphomagenesis by up-regulating a subset of notch target genes. PLoS One 2009, 4(8):e6678.
41. Puente X.S., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475(7354):101-105.
42. Fabbri G., et al. Analysis of the chronic lymphocytic leukemia coding genome: role of Notch1 mutational activation. J. Exp. Med. 2011, 208(7):1389-1401.
43. Borlado L.R., et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 2000, 14(7):895-903.
44. Rodriguez-Borlado L., et al. Phosphatidylinositol 3-kinase regulates the CD4/CD8 T cell differentiation ratio. J. Immunol. 2003, 170(9):4475-4482.
45. Swat W., et al. Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood 2006, 107(6):2415-2422.
46. Barbee S.D., Alberola-Ila J. Phosphatidylinositol 3-kinase regulates thymic exit. J. Immunol. 2005, 174(3):1230-1238.
47. Sinclair L.V., et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat. Immunol. 2008, 9(5):513-521.